Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Importance and hurdles to drug discovery for neurological disease.

Berger JR, Choi D, Kaminski HJ, Gordon MF, Hurko O, D'Cruz O, Pleasure SJ, Feldman EL.

Ann Neurol. 2013 Sep;74(3):441-6. doi: 10.1002/ana.23997. Review.

2.

Drug development for rare mitochondrial disorders.

Hurko O.

Neurotherapeutics. 2013 Apr;10(2):286-306. doi: 10.1007/s13311-013-0179-4. Review.

3.

Target-based drug discovery, genetic diseases, and biologics.

Hurko O.

Neurochem Int. 2012 Nov;61(6):892-8. doi: 10.1016/j.neuint.2012.01.016. Epub 2012 Jan 27. Review.

PMID:
22306775
4.

The ADNI Publication Policy: commensurate recognition of critical contributors who are not authors.

Hurko O, Black SE, Doody R, Doraiswamy PM, Gamst A, Kaye J, Obisesan TO, Rusinek H, Scharre D, Sperling R, Weiner MW, Green RC; ADNI Data and Publication Committee.

Neuroimage. 2012 Feb 15;59(4):4196-200. doi: 10.1016/j.neuroimage.2011.10.085. Epub 2011 Nov 4.

5.

Detecting global and local hippocampal shape changes in Alzheimer's disease using statistical shape models.

Shen KK, Fripp J, Mériaudeau F, Chételat G, Salvado O, Bourgeat P; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2155-66. doi: 10.1016/j.neuroimage.2011.10.014. Epub 2011 Oct 14.

PMID:
22037419
6.

Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data.

Cho Y, Seong JK, Jeong Y, Shin SY; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2217-30. doi: 10.1016/j.neuroimage.2011.09.085. Epub 2011 Oct 8.

PMID:
22008371
7.

BEaST: brain extraction based on nonlocal segmentation technique.

Eskildsen SF, Coupé P, Fonov V, Manjón JV, Leung KK, Guizard N, Wassef SN, Østergaard LR, Collins DL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2362-73. doi: 10.1016/j.neuroimage.2011.09.012. Epub 2011 Sep 16.

8.

Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.

McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

Radiology. 2011 Jun;259(3):834-43. doi: 10.1148/radiol.11101975. Epub 2011 Apr 6.

9.

Valuation of biomarkers.

Hurko O, Jones GK.

Nat Rev Drug Discov. 2011 Apr;10(4):253-4. doi: 10.1038/nrd3417. No abstract available.

PMID:
21455229
10.

Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.

Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW; Alzheimer's Disease NeuroImaging Initiative.

Brain. 2011 Apr;134(Pt 4):1077-88. doi: 10.1093/brain/awr044. Epub 2011 Mar 22.

11.

Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.

Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative, Goate AM.

PLoS One. 2011 Feb 9;6(2):e15918. doi: 10.1371/journal.pone.0015918.

12.

Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.

Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Nov;67(11):1370-8. doi: 10.1001/archneurol.2010.284.

13.

Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice.

Hurko O, Boudonck K, Gonzales C, Hughes ZA, Jacobsen JS, Reinhart PH, Crowther D.

Int J Alzheimers Dis. 2010 Oct 11;2010:864625. doi: 10.4061/2010/864625.

14.

Future drug discovery and development.

Hurko O.

Mol Genet Metab. 2010;100 Suppl 1:S92-6. doi: 10.1016/j.ymgme.2010.01.010. Epub 2010 Jan 29.

PMID:
20189856
15.

The uses of biomarkers in drug development.

Hurko O.

Ann N Y Acad Sci. 2009 Oct;1180:1-10. doi: 10.1111/j.1749-6632.2009.04946.x.

PMID:
19906255
16.

Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch.

Chavez JC, Hurko O, Barone FC, Feuerstein GZ.

Stroke. 2009 Oct;40(10):e558-63. doi: 10.1161/STROKEAHA.109.559914. Epub 2009 Sep 10. Review.

17.

Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1.

Shen S, Lang B, Nakamoto C, Zhang F, Pu J, Kuan SL, Chatzi C, He S, Mackie I, Brandon NJ, Marquis KL, Day M, Hurko O, McCaig CD, Riedel G, St Clair D.

J Neurosci. 2008 Oct 22;28(43):10893-904. doi: 10.1523/JNEUROSCI.3299-08.2008.

18.

Multimodal magnetic resonance imaging for assessing evolution of ischemic penumbra: a key translational medicine strategy to manage the risk of developing novel therapies for acute ischemic stroke.

Chavez JC, Zaleska MM, Wang X, Wood A, Hurko O, Pangalos MN, Feuerstein GZ.

J Cereb Blood Flow Metab. 2009 Jan;29(1):217-9. doi: 10.1038/jcbfm.2008.103. Epub 2008 Sep 3.

PMID:
18766199
19.

Drug development for CNS disorders: strategies for balancing risk and reducing attrition.

Pangalos MN, Schechter LE, Hurko O.

Nat Rev Drug Discov. 2007 Jul;6(7):521-32. Review.

PMID:
17599084
20.

The impact of preclinical drug safety on R&D productivity.

Hurko O.

Expert Opin Drug Discov. 2006 Sep;1(4):369-72. doi: 10.1517/17460441.1.4.369.

PMID:
23495908

Supplemental Content

Loading ...
Support Center